TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen

TransCode Therapeutics (NASDAQ:RNAZ) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright decreased their price target on shares of TransCode Therapeutics from $560.00 to $280.00 and set a “buy” rating on the stock in a research note on Wednesday, April 16th.

TransCode Therapeutics Price Performance

NASDAQ RNAZ opened at $6.97 on Friday. TransCode Therapeutics has a 12 month low of $6.15 and a 12 month high of $1,838.76. The stock’s 50 day moving average is $11.98 and its 200 day moving average is $1,617.06.

TransCode Therapeutics (NASDAQ:RNAZ) last released its quarterly earnings data on Wednesday, May 21st. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.00) by $1.40. As a group, equities research analysts expect that TransCode Therapeutics will post -4.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TransCode Therapeutics

An institutional investor recently bought a new position in TransCode Therapeutics stock. Warberg Asset Management LLC bought a new stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $25,000. Warberg Asset Management LLC owned about 0.21% of TransCode Therapeutics as of its most recent filing with the Securities and Exchange Commission.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.